November 16th, 2026FDA Updates Aficamten Label With MAPLE-HCM Data in Obstructive HCMAficamten's label now includes MAPLE-HCM data, in which aficamten monotherapy improved peak VO2 by 2.3 mL/kg/min more than metoprolol at 24 weeks.Read more
November 17th, 2026Don't Miss a Beat: How Prediction Markets Could Threaten Clinical Trial IntegrityAnkeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.Read more
November 10th, 2026Don't Miss a Beat: What Lp(a)HORIZON and ZEUS Teach About Clinical Trial ScienceLp(a)HORIZON and ZEUS hit their biomarker targets but not MACE. Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, unpack both at AHA 2026.Read more
November 9th, 2026The HCPFive: Top News for Healthcare Providers from the Week of 11/1Stay updated with the latest healthcare breakthroughs, including 96-week durability data for GSK’s bepirovirsen in hepatitis B, and more.Read more
November 9th, 2026Asundexian Receives FDA Approval for Secondary Stroke PreventionThe FDA approved asundexian with antiplatelet therapy after noncardioembolic ischemic stroke or high-risk TIA, based on OCEANIC-STROKE data.Read more
November 19th, 2026ABCs in Dermatology: Evolving Therapies and Dermatology's Role in Cutaneous Lupus CareAckerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.Read more
November 19th, 2026Q&A: Interpreting Pediatric Nemolizumab Data for AD, With Lawrence Eichenfield, MDLawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.Read more
November 18th, 2026What FAERS Anaphylaxis Data Can and Cannot Tell Biologic Prescribers In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next. Read more